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Abstract
Nitric oxide signals through activation of soluble guanylyl cyclase (sGC), a heme-containing heterodimer. NO binds to the
heme domain located in the N-terminal part of the b subunit of sGC resulting in increased production of cGMP in the
catalytic domain located at the C-terminal part of sGC. Little is known about the mechanism by which the NO signaling is
propagated from the receptor domain (heme domain) to the effector domain (catalytic domain), in particular events
subsequent to the breakage of the bond between the heme iron and Histidine 105 (H105) of the b subunit. Our modeling of
the heme-binding domain as well as previous homologous heme domain structures in different states point to two regions
that could be critical for propagation of the NO activation signal. Structure-based mutational analysis of these regions
revealed that residues T110 and R116 in the aF helix-b1 strand, and residues I41 and R40 in the aB-aC loop mediate
propagation of activation between the heme domain and the catalytic domain. Biochemical analysis of these heme mutants
allows refinement of the map of the residues that are critical for heme stability and propagation of the NO/YC-1 activation
signal in sGC.
Citation: Baskaran P, Heckler EJ, van den Akker F, Beuve A (2011) Identification of Residues in the Heme Domain of Soluble Guanylyl Cyclase that are Important
for Basal and Stimulated Catalytic Activity. PLoS ONE 6(11): e26976. doi:10.1371/journal.pone.0026976
Editor: Karl-Wilhelm Koch, University of Oldenburg, Germany
Received May 22, 2011; Accepted October 7, 2011; Published November 9, 2011
Copyright:  2011 Baskaran et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health Grants GM067640 (to AB) and HL075329 (to FvdA). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: focco.vandenakker@case.edu (FvdA); annie.beuve@umdnj.edu (AB)
¤ Current address: School of Medicine and Dentistry, Aab Cardiovascular Research Institute, University of Rochester, Rochester, New York, United States of America
. These authors contributed equally to this work.
Introduction
Physiologically, the NO-cGMP signaling pathway is critically
involved in vascular homeostasis via smooth muscle relaxation
and inhibition of platelet aggregation [1]. Pathophysiologically,
dysfunction of this pathway is involved in the development of
atherosclerosis and hypertension. Binding of NO to the heme of
sGC stimulates several hundred-fold the catalytic production of
cGMP from the substrate GTP. A key early event that leads to
increased sGC catalytic activity is the NO-mediated breakage of
the bond between the heme iron and His105 of the b subunit of
sGC (for recent review see [2,3,4]). sGC is active as an
heterodimer organized in three major domains: the N-terminal
domain of the b subunit contains the heme (the N-terminal
portion of the a subunit has unknown function, but could
interact with the sGC activator YC-1); a central domain formed
by the dimerization domain and a coiled-coil helix; a catalytic
domain formed by a head-to-tail association of the C-termini of
the two subunits, containing the catalytic site and a pseudo-
symmetric regulatory site. We and others have solved the
structures of (mostly) prokaryotic analog of those domains
including the dimerization/PAS fold domain [5], the sGC b1
coiled-coil domain [6], the catalytic domain [7,8] and the heme
domain (HNOX) [9,10,11]. However, no crystal structure of the
whole sGC molecule exists, greatly impairing our ability to
understand the interactions between those different domains, the
function of those interactions and the mechanisms by which NO
signaling is transmitted to the catalytic domain to increase
cGMP formation. Analysis of inactive or active structures of the
HNOX domains [11,12,13] and molecular simulations [14]
indicate that two regions in the heme domain are subjected to
major shifts relative to each other upon binding of NO: the aB-
aC loop and more noticeably the aF helix-b1 strand loop.
Furthermore, the aB-aC loop contains residues D44 and D45,
which previously have been shown to be involved in heme
incorporation and sGC signal transduction, respectively [15].
These major conformational shifts suggest that these regions of
the heme domain could participate in the downstream
propagation of the NO binding signal [16]. Our homology
modeling studies (Fig. 1) identified a number of partially solvent-
exposed residues in those two regions, hence with the potential of
being involved in interaction with other sGC subdomains for
activation signal propagation. To probe these residues’ impor-
tance regarding activation, we first conducted an initial screening
in COS-7 cells to identify mutants of interest based on their
response to NO donors, protoporphyrin IX or YC-1. Four
mutants were subsequently purified and their mechanism of
activation thoroughly characterized.
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Homology modeling of the heme domain of the b1
subunit (HNOX) predicts residues involved in NO
mediated activation
Figure 1 depicts a close-up view of the homology model of the
HNOX heme domain of rat sGC with the two regions of the heme
domain that are anticipated to shift upon NO binding relative to
each other based on previous structural studies of a homologous
heme domain [12]. We predicted that the solvent exposed residues
linking the aB-aC helixes and aF-b1 strand region, and flanking
E138 residue, could be involved in the interactions with the
catalytic domain and/or other sGC subdomains and propagation
of the NO signal. This hypothesis was tested by mutational
analysis in COS-7 transfected cells.
Alanine scanning of residues predicted to be involved in
propagation of NO activation
For initial screening in a cell-based system, residues in the aF-b1
region (T110, I111, G114, R116, E138) and in the aB-aC loop
(I41, R40) were replaced with alanine (A) by site directed
mutagenesis. Following transfection in COS-7 cells that do not
contain endogenous sGC, cytosolic fractions of WT and mutants
were prepared and activity measured under basal (un-stimulated)
condition and in the presence of 100 mM Protoporphyrin IX
(PPIX), 100 mM YC-1, 100 mM of the NO-donor SNAP, or
100 mM each of YC-1 and SNAP. Table 1 summarizes the basal
or stimulated activities of WT and mutant enzymes transiently
expressed in COS-7 cells. The levels of expression were similar for
WT and mutants, indicating that stability and expression of a and
b subunits were not affected by the mutations (Figure S1).
In the aF-b1 region, in comparison to the WT and the other
mutants, the mutant T110A had an elevated basal activity; mutant
R116A was more responsive to PPIX. For WT and mutants other
than R116A, PPIX activation was weak, probably because the
effect of PPIX is difficult to assess in broken cells. Mutant G114A
and E138A were readily activated by YC-1, NO and YC-1+ NO
in a manner similar to the WT. I111A had a decreased basal
activity and was less responsive to activators in comparison to the
WT. These results suggested that residues of the aF region have
different roles: T110 could be involved in modulation of basal
activity, R116 could be important for heme stabilization while
mutation of E138 did not lead to drastic changes suggesting a
limited role for this residue under the tested conditions. E138A
and I111A, which had only decreased NO response, and G114A
with characteristics similar to WT, were not pursued for further
studies.
In the aB-aC loop, R40 replacement resulted in a drastic
decrease not only in basal activity but also in stimulated activity in
response to PPIX, YC-1, NO or to the combination of NO+YC-1.
Interestingly, replacement of I41, the next residue on the loop, led
to opposite characteristics, as I41A was strongly activated by YC-
1, NO and to a lesser extent by PPIX and by the combination
Figure 1. Close-up view of the heme-binding region of a
homology model of the heme domain of sGC. The heme (green)
and its H105 ligand are depicted. Residues targeted for mutagenesis in
the region between the aB-aC helices are colored brown, targeted
residues in the aF-b1 strand region are shown in magenta and the
flanking E138 residue in yellow. The aC helix, b1 strand, and the aF helix
containing the heme-liganding residue H105 are labeled. Residues
Y135, S137, and R139 as part of the YxSxR heme binding motif are
shown in grey with the residues labeled.
doi:10.1371/journal.pone.0026976.g001
Table 1. Basal and stimulated activities of wild type and HNOX mutants in COS-7 cells.
basal PPIX, 100 mM YC-1, 100 mM SNAP 100 mM
SNAP, 100 mM
+YC-1, 100 mM
spec. act. % of WT spec. act. fold st spec. act. fold st spec. act. fold st spec. act. fold st
WT 22967 100 431642 1.9 1430663 6.2 33286102 14.5 34026370 14.8
aF-b1 region T110A 591660 254 8006104 1.4 16916263 2.9 23806254 4 25776224 4.4
I111A 129675 6 2 8 5 618 2.2 8516197 6.6 7726183 6 14546303 11.3
G114A 146625 64 334624 2.3 13046188 8.9 13556242 9.3 2752666 18.7
R116A 194622 84 7256115 3.7 6946161 3.6 12456201 6.4 13726109 7.1
E138A 195612 84 38565 2.0 20066163 10.3 29046337 14.9 44236225 22.7
aB-aC
loop
R40A 2964 13 68615 2.3 129615 4.5 125614 4.3 341614 11.6
I41A 134621 58 340616 2.5 1399672 10.5 30266348 22.6 34656122 25.8
Specific activities (spec. act.) are expressed in pmol. min
21.m g
21 of cytosolic fraction 6 SEM and were measured from 2 to 3 independent transfections. Each assay
under each condition was repeated three times and in duplicate. Fold stimulation (fold st) strongly lower or higher than WT is in italic and in bold, respectively. Cytosolic
fractions were prepared as described in Material and Methods.
doi:10.1371/journal.pone.0026976.t001
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further studies.
To determine the involvement of the above residues in
modulation of basal activity, in heme stability and understand
the mechanisms of propagation of NO and YC-1 activation,
several of the mutants were purified for spectral and kinetics
analyses.
Purification and heme content of WT and mutants
Mutant and WT were expressed and semi-purified as
described in Material and Methods. At elution, absorbance was
monitored at 431 nm, which is the expected absorbance for non-
stimulated heme-containing sGC (Fig. 2 A–C). Absorbance was
also measured at 280 nm for total protein concentration. The
ratio of total protein to heme bound protein of the WT and
mutants was initially used to estimate heme content (Fig. 2D)
with the caveat that WT and mutants were partially purified
(Coomassie staining, Figure S2). For the aF-b1l o o pr e s i d u e s ,
T110A and R116A retain the heme only partially, as reflected in
the ratio A431/A280 nm when compared to WT (Fig. 2D). In
the aB-aC loop, the replacement of R40 and I41 led to opposite
A431/A280 values (Fig. 2B and 2D). R40A was mostly in apo
form with an A431/A280 ratio of 0.04 (Fig. 2D and Figure S3).
Western blot analysis (insets) showed that for all purified mutants
both subunits were equally expressed, most likely reflecting a
stable heterodimer. Overall, the WT and mutants have lower
values of heme content (expected value of 1). To determine
whether this was due to poor heme loading, we measured the full
spectrum (600 to 240 nm) in the absence or presence of hemin.
The full spectrum indicated lower maxima absorbance ratio
A430/A280 (Fig. 2E and Figure S3 and Figure S4). Interestingly,
the mutation R116A shifted the heme Soret band from 431 nm
to 410 nm. Values of heme content of 1 for T110A and close to 1
for WT and I41A were obtained upon addition of 5 mMh e m i n
(Fig. 2E). On the other hand, mutant R40A and R116A were
only 50% reconstituted with hemin. In summary, mutant R40A
and R116A have partially lost affinity for the heme whereas
mutants T110A and I41A have decreased stability for the heme
compared to WT.
Basal and stimulated activities of purified WT and
mutants
Compared to basal activity, the purified WT was stimulated 12-
fold by 10 mM PPIX, 8-fold by 100 mM YC-1, 59-fold by 1 mM
DEA-NO and 90-fold by 10 mM YC-1+10 mM DEA-NO (Fig. 3
and Table S1).
In the helix aF-b1 region (Fig. 3A), mutant T110A has
several interesting characteristics; first, as in the initial screening
in COS-7 cells, the purified mutant showed a 2-fold increase of
its basal activity compared to WT (Table S1). Second, it was
stimulated 28-fold by PPIX (vs. 12-fold for the WT) while its
response to NO, YC-1 or NO+YC-1 was similar to WT but
decreased if the fold-stimulation compared to basal was taken
into account. The strong stimulation by PPIX could be
explained by the existence of an apo form of the mutant, in
addition to the heme-bound form as the T110A A430/A280
ratio was low compared to WT. Yet, reconstitution with PPIX
expressed as function of the ratio of A410 nm (expected
absorbance for PPIX occupying the heme domain) over
A280 nm indicated a lower value for T110A compared to WT
(Fig. 2E and Figure S4). This suggested a higher PPIX activation
in comparison to WT (Table S1). These characteristics,
including high response to PPIX but with lower heme content
were also seen in mutant R116A. R116A, unlike T110A, does
not display high basal activity and had lower response to DEA-
NO. Overall, T110A seems to be more sensitive to NO and
PPIX activation (Table S1) than WT, considering its low A430/
A280 and A410/A280 ratios. As such, the response to PPIX and
NO was further studied in mutant T110A by conducting
concentration-response curves (see below).
In the aB-aC loop (Fig. 3B), mutant R40A did not respond to
NO as expected for a heme-depleted mutant but was also
unresponsive to YC-1, to the combination of DEA-NO+YC-1,
and to PPIX indicating that this mutation drastically affects not
only the heme stability but the overall catalytic activity. As R40A
expression of both subunits was not affected, these results support
the idea that the stability of the heme domain is critical for any
type of activity including basal catalytic activity. In addition, R40A
was only partially reconstituted by hemin or PPIX suggesting a
profound alteration of the heme binding pocket (Fig. 2E). In sharp
contrast, mutant I41A, which displays a low A430/A280 ratio on
the full spectrum (Fig. 2E and Figure S3 and Figure S4), was
highly stimulated by PPIX (.16-fold), which was confirmed by the
highest PPIX reconstitution value (A410/A280 ratio, Fig. 2E).
I41A had a decreased response to DEA-NO (in comparison to
WT), and DEA-NO+YC-1, while response to YC-1 was similar to
WT. To further investigate mutant I41A, dose response curves to
PPIX and DEA-NO were conducted in parallel with WT and
mutant T110A.
Dose response curves to NO and PPIX of WT, T110A and
I41A
In response to increasing concentrations of DEA-NO (Fig. 4A),
the maximal velocity (Vmax) was slightly higher for WT
(3890.16167.5 nmol.min
21.mg
21) than for T110A and I41A
(2812.4677.6 and 2915.1654.3 nmol.min
21.mg
21,r e s p e c t i v e l y )
whereas the EC50 for DEA-NO of WT and T110A was similar
(0.1560.04 mMv s .0 . 1 6 60.02 mM) but higher in I41A
(0.5060.05 mM). The slight decrease in Vmax at saturating
concentrations of DEA-NO together with unchanged EC50
(compared to WT) suggest that T110 is involved in the efficacy
of stimulation by DEA-NO rather than the affinity of NO for the
heme. On the other hand, the mutation I41A negatively affects
efficacy and affinity of DEA-NO. For T110A and I41A, Vmax is
reached at higher concentration of DEA-NO, which is probably
due to heme depletion as both mutants show a decrease in the
ratio of maxima A430/280 in the full spectrum measurement
(Fig. 2E and Figure S3). Conversely, T110A and to a lesser
extent I41A were more responsive than WT to PPIX (Fig. 4B);
T110A exhibited a Vmax 4-fold and 2.5-fold higher than WT and
I41A, respectively (53696344 nmol.min
21.mg
21 vs. 1325680
and 20186138 nmol.min
21.mg
21). Higher Vmax for I41A in
response to PPIX correlated with a higher PPIX reconstitution
compared to WT (Fig. 2E). The high activation by PPIX of
T110A could partially be explained by a mixture of apo and
heme-bound forms for T110A. However, the mixture of apo and
heme-bound forms for T110A does not explain the only slightly
reduced response to DEA-NO of T110A compared to WT and
the high activation by PPIX (considering the low PPIX
reconstitution value). As such, T110A appears more responsive
than WT to DEA-NO and PPIX stimulation. To better
understand these observations, activation in presence of both
PPIX (10 mM) and DEA-NO (1 mM )w a sa s s a y e d .F i g .4 C
indicates that at these concentrations, the effect of the two
activators is not additive for the WT and mutants; on the
contrary, the combined DEA-NO/PPIX-stimulated activity is
less than the NO-stimulated activity, which could be explained
by the fact that 10 mM PPIX, by displacing the heme, lowers the
Probing NO Signal Propagation in H-NOX Domain
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similarly stimulated in response to DEA-NO or PPIX or both,
which could suggest that two populations (apo and heme-bound
form) are present but that the DEA-NO efficacy and PPIX
activation are enhanced in T110A.
Discussion
In spite of studies that identified residues critical for the heme
stability and binding [17,18] and that described inhibitory
interactions between the heme domain and the catalytic domain
Figure 2. Purification of Wild Type and mutants. 2A–B: representative spectra of purification of mutants at 431 nm, the expected absorbance
for the heme-containing enzyme. All mutants had similar levels of expression as assessed by immunoblot with antibodies against a and b subunit of
sGC after electrophoresis of ,0.5 mg of semi-purified protein on a 7.5% Tris-HCl gel (insets). 2C: representative elution profile of purification of WT.
2D: Table of purification with ratio of heme-containing sGC (431 nm) over protein total concentration (280 nm) from the elution, measured as
described in Material and Methods; values are expressed in absorbance unit (mAU). Elution as a function of salt concentration is indicated (NaCl, mM).
Measurement at 393 nm to estimate oxidized heme-containing sGC was not significantly different between WT and mutants (not shown). 2E: Table of
full spectrum values. UV-vis was recorded as described in Material and Methods (see also Figure S3) and the ratio of maximum absorption for WT and
mutants between 410 and 430 nm over maximum absorption at 280 nm was calculated in the absence or presence of hemin (5 mM) and PPIX (5 mM)
after heme reduction with 5 mM DTT. Max: Maxima. Each mutant was purified at least three times (6S.E.M.) and WT was purified six times (6 S.E.M.).
UV-vis collection of the various Soret bands for WT and mutants are shown in Figure S3 and Figure S4.
doi:10.1371/journal.pone.0026976.g002
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nism of propagation of the NO signal between the receptor-heme
domain (at the NH2-terminal of the sGC molecule) to the effector-
catalytic domain (at the C-terminus of sGC). It is accepted that
breaking of the His-iron heme bond upon binding of NO is a key
step in inducing conformational changes leading to increase
catalysis in the catalytic domain [21]. In parallel, it is clear that
large shifts in regions of the heme domain occur during activation.
How these shifts lead to increased catalytic activity is similarly
unresolved.
To address these fundamental questions, we first carried out
homology modeling of the rat sGC heme domain to identify
solvent-exposed residues in the regions that exhibit the largest
shifts, the aF helix-b1 strand and the flanking aB-aC loop, as
recently studied in our structure of the sGC activator BAY 58–
2667 bound to Ns HNOX [22] and in our structure-function
analysis of residues involved in NO propagation downstream of
the His-iron breakage [16]. As such, these two regions could be the
missing link to propagate activation, i.e. be directly involved in
interaction between the heme domain and the catalytic domains as
proposed by others [20] or induce conformational changes,
transmitted by the intermediary domains (PAS and coiled-coil
domains).
In the aF helix region, replacement of residue R116 with Ala
led to decreased activation by YC-1, DEA-NO and YC-1+DEA-
NO, as expected if this region is involved in propagation of
activation. Interestingly, the full UV-Vis spectrum of the semi-
purified R116A revealed that the Soret band absorption
maximum was blue-shifted from 431 nm to 410 nm, which could
indicate a weakening and breakage of the His-iron bond in this
mutant [23]. In addition, the reconstitution with hemin was only
partial compared to WT or T110A of the aF helix (Fig. 2E). These
data suggest that the replacement of residue R116 with Ala not
only affect the spectral properties of the heme group but also
affects heme stability and affinity. However, in the same region the
replacement of T110 with Ala only slightly reduced the Vmax of
the DEA-NO response curves. Interestingly, T110A also displayed
a 2-fold increase in basal activity compared to WT, which partially
supports the idea that under basal conditions, the heme domain
has an inhibitory effect on the catalytic domain [19], as
replacement with Ala could partially relieve the inhibition.
Furthermore, considering the low heme content of T110A, the
response of T110A to DEA-NO was high compared to WT while
EC50 was similar. We speculate that T110 is a key residue for
interactions between the heme and catalytic domains. This
supports our most recent structural analysis with the compound
BAY58–2667 that predicted the largest shift resided in the aF
carboxy-terminus, which includes T110 [22]. Those results suggest
that T110 is a critical residue for basal activity and NO activation
by ‘‘loosening’’ a potential inhibitory interaction between the
catalytic and heme domains. This will also explain the significant
higher activation of T110A by PPIX over WT despite a lower
PPIX reconstitution, in addition to the fact that the higher
response to PPIX is also partially due to the T110A apo form, as
observed previously with the R139 mutant [17]. Thus, T110 and
to a lesser extent R116 appear to be crucial residues for heme
stability/affinity as shown by the lower heme content and
increased PPIX response when replaced with Ala. The function
of these residues (T110, R116) in sGC is different from other
residues of the same aF helix, in particular D102 and F120 [16].
D102 and F120 are also involved in propagation of the NO signal
yet unlike T110 or R116, D102 is predicted to interact with the
backbone of F120 and with H105 via a molecule of water. As a
result, in mutant D102N the breakage of the His-iron bond and
the activation by NO were uncoupled [16]. These contrasting
phenotypes of mutants introduced in the same helix underscore
the fine-tuned mechanism of propagation of the NO signal from
the receptor heme domain to the effector catalytic domain of sGC.
Figure 3. Basal and stimulated activities of purified WT and
mutants. 3A: In the aF-b1 region, basal activity of a1/b1T110A as well
as PPIX activation of a1/b1T110A and a1/b1R116A were significantly
higher than WT. 3B: In the aB-aC loop, mutant a1/b1I41A exhibits a
significantly higher response to PPIX and significantly lower response to
DEA-NO compared to WT, yet sensitivity to DEA-NO +YC-1 was
comparable to WT. a1/b1R40A lost the ability to respond to any
activators. Measurements of activities were done at least three times on
50 ng of two to three independently semi-purified WT and mutants
with each assay done in duplicate under each condition. Results are
expressed in nmol cGMP. mg
21.min
21 6 S.E.M. Values and fold
stimulation are provided in Table S1.
doi:10.1371/journal.pone.0026976.g003
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aC loop led to opposite phenotype suggesting different roles in
propagation of activation. R40A was predicted to be located in the
surface contact region between heme and catalytic domains (Fig. 1
and [22]), and to act as a potential switch for activation as
described for D45 [15]. Instead, R40A led to a heme-depleted
enzyme unresponsive to the activators tested here. This is
reminiscent of the phenotypes of mutant D44A [15]; a potential
reason for depletion of the heme could be due to the introduction
of Ala in place of R40 (and of D44 in the study cited above),
resulting in a highly hydrophobic region (L38-V39-A40-I41-I42).
Such a hydrophobic region could potentially be more prone to
adopting an alternate conformation, as there are no longer
hydrophilic or charged residues that can provide conformational
specificity of this region. With this region being in close proximity
to the N-terminus of the heme domain which is involved in heme
propionate group binding [11], we anticipate that shifts in this
L38-I42 region upon mutating R40A will affect the position of the
N-terminal region and thus heme binding. Indeed, the reconsti-
tution with hemin was only partial in this mutant, as was the PPIX
reconstitution (Fig. 2E). On the other hand, I41A mutation
probably reduces hydrophobicity of this region, hence the heme
could be repleted in I41A mutant and the reconstitution with
PPIX was higher than WT. The decreased response of this mutant
to DEA-NO and higher basal activity suggest that I41 is important
for activation. I41 is also probably involved in heme stability as the
response of the mutant to PPIX is higher, in agreement with
higher PPIX reconstitution value and a lower A430/280 ratio
(Fig. 2E).
In summary, our studies and results in probing of the aF helix
and aB-aC loop regions of the heme sGC domain indicate their
involvement in propagation of NO-dependent and independent
activation and/or impact on heme stability.
Materials and Methods
Molecular modeling
Molecular modeling of the heme domain of sGCb1 is carried
out as described previously [12]. Molecular figure was made using
PYMOL (www.pymol.org).
Figure 4. Response of WT, a1/b1T110A and a1/b1I41A to DEA-NO, PPIX and both. 4A: DEA-NO concentration-response curve of purified WT
and mutants. cGMP production was measured as a function of increasing concentrations of DEA-NO. 4B: PPIX concentration-response curves of purified
WT and mutants. cGMP production was measured as a function of increasing concentrations of PPIX. 4C: Comparison of WT and mutants’ response to
DEA-NO (1 mM), PPIX (10 mM) and DEA-NO (1 mM)+PPIX (10 mM). Results are expressed in nmol cGMP. mg
21.min
21 6 S.E.M. Typically, 50 ng of semi-
purified enzyme was used per assay tube. Each experiment, carried out in duplicate, was repeated independently two or three times with two separate
purified preparations. For the concentration-response curves, EC50 and maximal velocity were determined using Sigmaplot software (version 11.0).
doi:10.1371/journal.pone.0026976.g004
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[a-
32P]-GTP is from PerkinElmer (MA, USA). DMEM from
ATCC (VA, USA) and antibiotic/antimycotic from Mediatech,
Inc. (VA, USA). The expressfect transfection reagent is from
Denville Scientific Inc. (NJ, USA) and SF900II SFM medium, FBS
and Gentamycin from Invitrogen. SNAP from EMD chemicals
(NJ, USA), DEA-NO from Axxora LLC (CA, USA). b sGC
antibody are from Cayman chemicals (MI, USA). 7.5% Tris-HCl
gels are from Bio-Rad Laboratories (CA, USA). All the other
reagents were from Sigma.
Cell cultures
COS-7 cells from ATCC (CRL-1651, VA, USA) were grown in
DMEM supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic (penicillin (100 IU/ml), streptomycin
(100 mg/ml) and Amphotericin B (0.25 mg/ml)). Sf21 cells were
seeded at 0.5610
6 cells/ml in 2 L of SF900II SFM medium
containing gentamycin (0.1 mg/ml) and 5% heat inactivated FBS
at 28uC with constant shaking.
Mutation, transfection in COS-7 cells and cytosolic
preparation of sGC
a1 and b1 subunits of rat cDNA subcloned in pCMV5 vector
[24] were mutated using Quikchange Site-Directed Mutagenesis
Kit (Agilent Technologies, CA, USA) and confirmed by
sequencing. COS-7 cells were transiently transfected for 48 h
with a1 and b1W To rb1 mutant cDNA as described before[25].
After 48 h, transfected COS-7 cells were washed in cold
phosphate buffered saline (PBS) and scraped in homogenization
buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 1 mM DTT,
protease inhibitors). Cytosol was prepared by sonication and
centrifugation at 16000 rpm for 10 min at 4uC to remove the
membrane fraction and cell debris. Expression levels of sGC WT
and mutants were assessed by immunoblot with antibodies against
a and b after electrophoresis of 8–10 mg of cytosolic protein on a
7.5% Tris -HCl gel.
Construction and purification of mutant in insect Sf21
cells/baculovirus system
Mutations were introduced in the b1 subunit with an His-tag at
the C-terminus and cloned in the baculovirus transfer vector
pbacPAK8 as described previously [25]. Recombinant baculovirus
were produced in Sf21 cells (Invitrogen, CA, USA) by co-
transfection of the pbacPAK8 construct with the linear BacPak6
viral DNA (Clontech, CA, USA). Sf21 cells were co-infected with
a1- and b1-Histag WT or mutant containing viruses and grown for
48 hours. The recombinant protein was purified in two steps using
a cobalt column followed by Mono Q anion exchange column, as
previously described [25]. Chromatographic separation was
performed at a flow rate of 0.5 mL/min. The elution pattern at
431, 280 and 393 nm was recorded using Unicorn program of the
GE A ¨KTA HPLC/FPLC purifier. The level of purification was
directly estimated by the ratio OD431 nm/OD280 nm simulta-
neously measured (similar background noise) by the GE A ¨KTA
FPLC UV-900 detector (Table Figure 2D values). Each enzyme
was purified three (mutants) to six (WT) times. The fractions that
showed a peak at 431 nm were collected and snap frozen in 10%
glycerol for storage at 280uC.
UV-visible spectroscopy
UV-visible spectroscopy was carried out using a Shimadzu 2450
double monochromator spectrophotometer on the pooled frac-
tions collected above. Full spectra from 600 nm to 240 nm were
collected for semi-purified wild type and each mutant with 72–
80 uL (,600 ng) enzyme in a quartz microcuvette. Heme
reconstitution was carried out with both hemin and protoporphy-
rin IX (PPIX). 40–72 mL( ,575 ng) of enzyme was incubated with
5 mM hemin or 5 mM PPIX in the presence of 5 mM DTT (for
heme reduction) for 15 minutes at room temperature (25uC). The
reference cuvette contained the equivalent volume of 50 mM
HEPES, pH 8.0, 5 mM hemin or PPIX and 5 mM DTT also
incubated for 15 minutes. A new reference was prepared with
each new sample. The full spectrum from 600 nm to 240 nm was
collected. The heme content versus protein was compared as a
ratio of absorbencies at 280 nm and 431 nm corrected for baseline
for purified and hemin-reconstituted. The heme Soret peak for
PPIX was shifted to approximately 410 nm, so the ratio of
absorbencies at 280 nm and 410 nm corrected for baseline was
determined for the PPIX-reconstituted samples for comparison.
sGC activity assay
sGC activity was measured by the conversion of [a-
32P]cGMP
from [a-
32P]GTP as previously described [25]. For DEA-NO and
PPIX concentration-response curves of purified WT and mutants,
sGC activity was measured in duplicate and in the presence of ten
different concentrations of DEA-NO (ranging from 0.003 to
100 mM) and eight different concentrations of PPIX (ranging from
0.03 to 100 mM). The EC50 values were calculated from the
concentration-response curves that were established from three
independent experiments and corresponded to the concentration
of DEA-NO or PPIX that half-maximally activates the enzymes.
Statistical analysis
The results are expressed as mean 6 S.E.M from the data
derived from [a-
32P]GTP assay. Activity measurements in cytosol
of COS-7 cells were repeated three times, each in duplicates and
from two to three independent transfections. For purified enzyme
assays, two to three independent enzyme semi-purified prepara-
tions were used and assayed four times under each condition and
in duplicate. Student’s t test was used for statistical comparison
between groups and conditions with Sigmaplot version 11.0
software (Systat software, San Jose, CA). P,0.05 was considered
statistically significant.
Supporting Information
Figure S1 Western blot of WT and HNOX mutants transiently
expressed in COS-7 cells. Western blot analysis with antibodies
against the a and b subunits of WT and HNOX mutants
transiently expressed (48 h) in COS-7 cells. 10 mg of cytosolic
fraction were electrophorated on 8% SDS-gel. A and B are two
separate transfections.
(PDF)
Figure S2 Coomassie blue staining of semi-purified WT and
HNOX mutants. Approximately 5 mg of each WT and mutants
were electrophorated on an SDS-gel under reducing, denaturing
conditions and stained with Coomassie.
(PDF)
Figure S3 Spectra of absorbance of semi-purified WT and
mutants. UV-Vis (240–600 nm) was collected as described under
Material and Methods. Arrow indicates the maximum peak
between 410 and 430 nm. No peak was detectable for R40A.
(PDF)
Figure S4 Spectra of absorbance of semi-purified WT and
mutants in the absence or presence of 5 mM hemin and PPIX.
Heme was reduced with 5 mM DTT. UV-Vis (240–600 nm, only
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and Methods.
(PDF)
Table S1 Comparison between purified WT and mutants of
basal and stimulated activities. The values correspond to Fig. 3
and include the fold stimulation of each activator compared to
basal activity for WT and mutants and percentage of basal activity
of the mutants compared to WT. Specific activity is expressed in
nmol.min21.mg216 SEM. Stim.: stimulation. *: The higher
basal activity of R40A is explained by a higher amount of sGC in
the fraction used, i.e. the fraction eluted with high salt (,500 mM)
with some absorbance at 431 nm as well.
(PDF)
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